Skip to content

How will Annex 1 change fill/finish processes?

Share to Xing
Share to LinkedIn
Share to Facebook
Share to Twitter
Share to Whatapp
Share asa email

Which implications will EU GMP Annex 1 have for sterile fill/finish processes? How will it change the way we work in the pharmaceutical industry? And which technologies are best suited?


Jürgen Metzger featured in Pharmaceutical Technology

On December 20, 2017, the European Commission published the long-awaited revision draft of EU GMP Annex 1. Even before its release, this document triggered many heated discussions, which have further intensified after publication. Topics include material classification for sterile transfers, detailed risk assessment procedures for processes and the associated environment, more operational qualification (OQ) testing, and laminar flow (LF) conditions for loading and preparing machines for production as well as reducing the overall risk from human intervention.

Our expert for barrier systems, Jürgen Metzger, discusses some of the most important issues in an in-depth article, which was recently published in Pharmaceutical Technology.

Read the full article in Pharmaceutical Technology here.

Jürgen Metzger is Barrier Systems & Process Specialist at Syntegon Technology. He started his career at Syntegon in 1999 in Crailsheim, Germany. Throughout his time in Germany, one of the main focus areas was isolator technology with aseptic filling machines and processes. Since April 2017, Metzger has been responsible for barrier systems technology in Minneapolis, MN.

Interested in processing & packaging solutions?

Interested in processing & packaging solutions?

Get in touch with us!

Spokesperson Product Communications Pharma
Syntegon Technology

Nicole König
Phone: +49 7951 402-648
Contact us